Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a
popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed …

The promise of tumor immunotherapy to significantly improve survival in patients who are
refractory to long-standing therapies, such as chemotherapy and radiation, is now being …

As a facultative intracellular bacterium, Listeria monocytogenes has adapted to live within
the cytosol of the host cell. It is actively taken up by antigen-presenting cells through …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

Active immunotherapy targeting dendritic cells (DCs) has shown great promise in preclinical
models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T …

The immunostimulatory characteristics and intracellular niche of Listeria monocytogenes
make it uniquely suitable for use as a live bacterial vaccine vector. Preclinical results …

Listeria monocytogenes has recently been exploited as a vector for targeting antigens to the
immune system. In the past year it has been shown to be particularly effective as a tumor …

For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …

Listeria monocytogenes is a facultative intracellular bacterium that enters professional
antigen-presenting cells by active phagocytosis. As a live bacterium, it induces antigen …

Active immunotherapy has shown great promise in preclinical models for the treatment of
infectious and malignant disease. Yet, these promising results have not translated into …